339 related articles for article (PubMed ID: 32133402)
21. Dysplastic Lipoma: A Distinctive Atypical Lipomatous Neoplasm With Anisocytosis, Focal Nuclear Atypia, p53 Overexpression, and a Lack of MDM2 Gene Amplification by FISH; A Report of 66 Cases Demonstrating Occasional Multifocality and a Rare Association With Retinoblastoma.
Michal M; Agaimy A; Contreras AL; Svajdler M; Kazakov DV; Steiner P; Grossmann P; Martinek P; Hadravsky L; Michalova K; Svajdler P; Szep Z; Michal M; Fetsch JF
Am J Surg Pathol; 2018 Nov; 42(11):1530-1540. PubMed ID: 30001242
[TBL] [Abstract][Full Text] [Related]
22. [Influence of neoadjuvant chemotherapy on microsatellite instability in gastric carcinoma].
Sun XW; Zhan YQ; Li W; Xu L; Li JT; Chen XJ; Zhang RH; Xu DZ
Ai Zheng; 2006 Dec; 25(12):1493-6. PubMed ID: 17166373
[TBL] [Abstract][Full Text] [Related]
23. Chemotherapy for resectable microsatellite instability-high gastric cancer?
Lordick F
Lancet Oncol; 2020 Feb; 21(2):203. PubMed ID: 32007193
[No Abstract] [Full Text] [Related]
24. Gastric cancer and concomitant renal cancer: a systematic immunohistochemical and molecular analysis.
Betge J; Pollheimer MJ; Schlemmer A; Hoefler G; Langner C
Oncol Rep; 2011 Sep; 26(3):567-75. PubMed ID: 21687951
[TBL] [Abstract][Full Text] [Related]
25. Perineural invasion after preoperative chemotherapy predicts poor survival in patients with locally advanced gastric cancer: gene expression analysis with pathologic validation.
Jhawer M; Coit D; Brennan M; Qin LX; Gonen M; Klimstra D; Tang L; Kelsen DP; Shah MA
Am J Clin Oncol; 2009 Aug; 32(4):356-62. PubMed ID: 19381079
[TBL] [Abstract][Full Text] [Related]
26. Predictive Value of ERCC1, ERCC2, and XRCC Expression for Patients with Locally Advanced or Metastatic Gastric Cancer Treated with Neoadjuvant mFOLFOX-4 Chemotherapy.
Yeh YS; Chen YT; Tsai HL; Huang CW; Ma CJ; Su WC; Huang CM; Huang MY; Hu HM; Lu CY; Wang JY
Pathol Oncol Res; 2020 Apr; 26(2):1105-1116. PubMed ID: 31077069
[TBL] [Abstract][Full Text] [Related]
27. Reconstruction of the gastric cancer microenvironment after neoadjuvant chemotherapy by longitudinal single-cell sequencing.
Chen Y; Yin J; Zhao L; Zhou G; Dong S; Zhang Y; Niu P; Ren H; Zheng T; Yan J; Li W; Ma P; Zhang C; Wei C; Church G; Li G; Zhao D
J Transl Med; 2022 Dec; 20(1):563. PubMed ID: 36474268
[TBL] [Abstract][Full Text] [Related]
28. [Effects of XELOX regimen as neoadjuvant chemotherapy on radical resection rate and prognosis in patients with advanced gastric cancer].
Zhao Q; Li Y; Tan BB; Tian Y; Jiao ZK; Zhao XF; Zhang ZD; Wang D; Yang PG
Zhonghua Zhong Liu Za Zhi; 2013 Oct; 35(10):773-7. PubMed ID: 24378101
[TBL] [Abstract][Full Text] [Related]
29. Mdm2 gene amplification in gastric cancer correlation with expression of Mdm2 protein and p53 alterations.
Günther T; Schneider-Stock R; Häckel C; Kasper HU; Pross M; Hackelsberger A; Lippert H; Roessner A
Mod Pathol; 2000 Jun; 13(6):621-6. PubMed ID: 10874665
[TBL] [Abstract][Full Text] [Related]
30. High-Throughput Mutation Profiling Changes before and 3 Weeks after Chemotherapy in Newly Diagnosed Breast Cancer Patients.
Tan SH; Sapari NS; Miao H; Hartman M; Loh M; Chng WJ; Iau P; Buhari SA; Soong R; Lee SC
PLoS One; 2015; 10(12):e0142466. PubMed ID: 26630576
[TBL] [Abstract][Full Text] [Related]
31. Profiling molecular regulators of recurrence in chemorefractory triple-negative breast cancers.
Hancock BA; Chen YH; Solzak JP; Ahmad MN; Wedge DC; Brinza D; Scafe C; Veitch J; Gottimukkala R; Short W; Atale RV; Ivan M; Badve SS; Schneider BP; Lu X; Miller KD; Radovich M
Breast Cancer Res; 2019 Aug; 21(1):87. PubMed ID: 31383035
[TBL] [Abstract][Full Text] [Related]
32. A new subtype of high-grade mandibular osteosarcoma with RASAL1/MDM2 amplification.
Guérin M; Thariat J; Ouali M; Bouvier C; Decouvelaere AV; Cassagnau E; Aubert S; Lepreux S; Coindre JM; Valmary-Degano S; Larousserie F; Meilleroux J; Projetti F; Stock N; Galant C; Marie B; Peyrottes I; de Pinieux G; Gomez-Brouchet A
Hum Pathol; 2016 Apr; 50():70-8. PubMed ID: 26997440
[TBL] [Abstract][Full Text] [Related]
33. Sequential endoscopic ultrasound identifies predictive variables for relapse-free follow-up after neoadjuvant chemotherapy in gastric cancer.
Bohle W; Zachmann R; Zoller WG
Scand J Gastroenterol; 2017; 52(6-7):754-761. PubMed ID: 28355948
[TBL] [Abstract][Full Text] [Related]
34. Efficacy of neoadjuvant chemotherapy with docetaxel, cisplatin and S-1 for resectable locally advanced gastric cancer.
Migita K; Nashimoto A; Yabusaki H; Matsuki A; Aizawa M
Int J Clin Oncol; 2016 Feb; 21(1):102-9. PubMed ID: 26017926
[TBL] [Abstract][Full Text] [Related]
35. Does neoadjuvant therapy alter KRAS and/or MSI results in rectal adenocarcinoma testing?
Ondrejka SL; Schaeffer DF; Jakubowski MA; Owen DA; Bronner MP
Am J Surg Pathol; 2011 Sep; 35(9):1327-30. PubMed ID: 21836482
[TBL] [Abstract][Full Text] [Related]
36. Core Biopsies from Prostate Cancer Patients in Active Surveillance Protocols Harbor PTEN and MYC Alterations.
Gandellini P; Casiraghi N; Rancati T; Benelli M; Doldi V; Romanel A; Colecchia M; Marenghi C; Valdagni R; Demichelis F; Zaffaroni N
Eur Urol Oncol; 2019 May; 2(3):277-285. PubMed ID: 31200842
[TBL] [Abstract][Full Text] [Related]
37. The Complex Network between MYC Oncogene and microRNAs in Gastric Cancer: An Overview.
Anauate AC; Leal MF; Calcagno DQ; Gigek CO; Karia BTR; Wisnieski F; Dos Santos LC; Chen ES; Burbano RR; Smith MAC
Int J Mol Sci; 2020 Mar; 21(5):. PubMed ID: 32150871
[TBL] [Abstract][Full Text] [Related]
38. Chromosomal instability rather than p53 mutation is associated with response to neoadjuvant cisplatin-based chemotherapy in gastric carcinoma.
Ott K; Vogelsang H; Mueller J; Becker K; Müller M; Fink U; Siewert JR; Höfler H; Keller G
Clin Cancer Res; 2003 Jun; 9(6):2307-15. PubMed ID: 12796400
[TBL] [Abstract][Full Text] [Related]
39. MDM2 Amplification in Intrahepatic Cholangiocarcinomas: Its Relationship With Large-Duct Type Morphology and Uncommon KRAS Mutations.
Kim SJ; Akita M; Sung YN; Fujikura K; Lee JH; Hwang S; Yu E; Otani K; Hong SM; Zen Y
Am J Surg Pathol; 2018 Apr; 42(4):512-521. PubMed ID: 29309301
[TBL] [Abstract][Full Text] [Related]
40. miR-494 acts as an anti-oncogene in gastric carcinoma by targeting c-myc.
He W; Li Y; Chen X; Lu L; Tang B; Wang Z; Pan Y; Cai S; He Y; Ke Z
J Gastroenterol Hepatol; 2014; 29(7):1427-34. PubMed ID: 24612089
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
